Edward Tenthoff
Stock Analyst at Piper Sandler
(3.04)
# 1,417
Out of 5,090 analysts
184
Total ratings
41.81%
Success rate
0.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Tenthoff
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRNA Moderna | Reiterates: Overweight | $69 → $63 | $25.49 | +147.20% | 13 | Nov 21, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | $45 → $70 | $64.67 | +8.24% | 12 | Nov 19, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Overweight | $5 → $6 | $2.04 | +194.84% | 2 | Nov 14, 2025 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Overweight | $449 → $489 | $464.56 | +5.26% | 15 | Oct 31, 2025 | |
| FULC Fulcrum Therapeutics | Reiterates: Overweight | $13 → $16 | $8.88 | +80.28% | 5 | Oct 30, 2025 | |
| KPTI Karyopharm Therapeutics | Reiterates: Overweight | $15 → $12 | $5.89 | +103.74% | 1 | Oct 9, 2025 | |
| CAMP Camp4 Therapeutics | Maintains: Overweight | $18 → $12 | $3.41 | +251.91% | 2 | Sep 15, 2025 | |
| NXTC NextCure | Maintains: Overweight | $36 → $15 | $12.93 | +16.01% | 5 | Jul 15, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Overweight | $105 | $58.85 | +78.42% | 7 | Jun 27, 2025 | |
| STRO Sutro Biopharma | Upgrades: Overweight | $20 | $8.81 | +127.01% | 7 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $7 | $1.17 | +496.10% | 1 | Jun 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 → $14 | $12.62 | +10.98% | 7 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $2 | $0.52 | +282.04% | 8 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $48 | $20.75 | +131.33% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $24 | $17.12 | +40.19% | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $78 | $27.87 | +179.87% | 4 | Dec 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $30 | $18.05 | +66.20% | 4 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $65 | $3.42 | +1,800.58% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $25.51 | +37.23% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $1.20 | +1,566.67% | 3 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.35 | +122.22% | 6 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $3 | $0.56 | +440.35% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $17.27 | -7.35% | 3 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $4 → $6 | $1.11 | +442.99% | 7 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.63 | +90.11% | 4 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $56 | $66.56 | -15.87% | 4 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $224 → $248 | $34.40 | +620.93% | 5 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $3.79 | +2,277.81% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $180 | $17.48 | +929.75% | 3 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $44 | $16.44 | +167.64% | 1 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $37 | $7.19 | +414.60% | 2 | May 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $2,246,640 → $651,200 | $1.38 | +47,188,305.80% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $250 → $354 | $916.31 | -61.37% | 4 | Nov 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $135 | $1.15 | +11,639.13% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $261 → $323 | $457.26 | -29.36% | 6 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $33 → $36 | $44.40 | -18.91% | 2 | Feb 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $25 | $1.42 | +1,664.29% | 2 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $150 | $0.75 | +19,873.37% | 1 | Jan 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $13,800 | $3.03 | +454,745.09% | 1 | Dec 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $722.83 | - | 11 | Feb 13, 2017 |
Moderna
Nov 21, 2025
Reiterates: Overweight
Price Target: $69 → $63
Current: $25.49
Upside: +147.20%
Arrowhead Pharmaceuticals
Nov 19, 2025
Maintains: Overweight
Price Target: $45 → $70
Current: $64.67
Upside: +8.24%
Inovio Pharmaceuticals
Nov 14, 2025
Reiterates: Overweight
Price Target: $5 → $6
Current: $2.04
Upside: +194.84%
Alnylam Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $449 → $489
Current: $464.56
Upside: +5.26%
Fulcrum Therapeutics
Oct 30, 2025
Reiterates: Overweight
Price Target: $13 → $16
Current: $8.88
Upside: +80.28%
Karyopharm Therapeutics
Oct 9, 2025
Reiterates: Overweight
Price Target: $15 → $12
Current: $5.89
Upside: +103.74%
Camp4 Therapeutics
Sep 15, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $3.41
Upside: +251.91%
NextCure
Jul 15, 2025
Maintains: Overweight
Price Target: $36 → $15
Current: $12.93
Upside: +16.01%
CRISPR Therapeutics AG
Jun 27, 2025
Reiterates: Overweight
Price Target: $105
Current: $58.85
Upside: +78.42%
Sutro Biopharma
Jun 16, 2025
Upgrades: Overweight
Price Target: $20
Current: $8.81
Upside: +127.01%
Jun 3, 2025
Assumes: Overweight
Price Target: $7
Current: $1.17
Upside: +496.10%
May 2, 2025
Reiterates: Overweight
Price Target: $24 → $14
Current: $12.62
Upside: +10.98%
Mar 20, 2025
Maintains: Overweight
Price Target: $4 → $2
Current: $0.52
Upside: +282.04%
Feb 28, 2025
Maintains: Overweight
Price Target: $53 → $48
Current: $20.75
Upside: +131.33%
Feb 7, 2025
Reiterates: Overweight
Price Target: $15 → $24
Current: $17.12
Upside: +40.19%
Dec 30, 2024
Reiterates: Overweight
Price Target: $78
Current: $27.87
Upside: +179.87%
Dec 2, 2024
Upgrades: Overweight
Price Target: $20 → $30
Current: $18.05
Upside: +66.20%
Nov 13, 2024
Maintains: Overweight
Price Target: $104 → $65
Current: $3.42
Upside: +1,800.58%
Oct 21, 2024
Initiates: Overweight
Price Target: $35
Current: $25.51
Upside: +37.23%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $1.20
Upside: +1,566.67%
Sep 17, 2024
Reiterates: Overweight
Price Target: $3
Current: $1.35
Upside: +122.22%
Jul 26, 2024
Maintains: Overweight
Price Target: $8 → $3
Current: $0.56
Upside: +440.35%
Jun 28, 2024
Reiterates: Overweight
Price Target: $16
Current: $17.27
Upside: -7.35%
Jun 17, 2024
Upgrades: Overweight
Price Target: $4 → $6
Current: $1.11
Upside: +442.99%
Mar 5, 2024
Maintains: Overweight
Price Target: $6 → $5
Current: $2.63
Upside: +90.11%
Feb 27, 2024
Maintains: Overweight
Price Target: $39 → $56
Current: $66.56
Upside: -15.87%
Aug 14, 2023
Maintains: Overweight
Price Target: $224 → $248
Current: $34.40
Upside: +620.93%
Dec 12, 2022
Initiates: Overweight
Price Target: $90
Current: $3.79
Upside: +2,277.81%
Sep 7, 2022
Maintains: Overweight
Price Target: $140 → $180
Current: $17.48
Upside: +929.75%
Aug 25, 2022
Maintains: Overweight
Price Target: $37 → $44
Current: $16.44
Upside: +167.64%
May 23, 2022
Maintains: Overweight
Price Target: $76 → $37
Current: $7.19
Upside: +414.60%
May 13, 2022
Maintains: Overweight
Price Target: $2,246,640 → $651,200
Current: $1.38
Upside: +47,188,305.80%
Nov 29, 2021
Upgrades: Overweight
Price Target: $250 → $354
Current: $916.31
Upside: -61.37%
Sep 20, 2021
Maintains: Overweight
Price Target: $105 → $135
Current: $1.15
Upside: +11,639.13%
Jul 30, 2021
Maintains: Overweight
Price Target: $261 → $323
Current: $457.26
Upside: -29.36%
Feb 16, 2021
Maintains: Overweight
Price Target: $33 → $36
Current: $44.40
Upside: -18.91%
May 12, 2020
Downgrades: Neutral
Price Target: $50 → $25
Current: $1.42
Upside: +1,664.29%
Jan 27, 2020
Initiates: Overweight
Price Target: $150
Current: $0.75
Upside: +19,873.37%
Dec 11, 2017
Initiates: Overweight
Price Target: $13,800
Current: $3.03
Upside: +454,745.09%
Feb 13, 2017
Upgrades: Overweight
Price Target: n/a
Current: $722.83
Upside: -